Advertisement
- United States
- /
- Medical Equipment
- /
- NasdaqGM:PRCT
PROCEPT BioRobotics First Quarter 2025 Earnings: Beats Expectations
PROCEPT BioRobotics (NASDAQ:PRCT) First Quarter 2025 Results
Key Financial Results
- Revenue: US$69.2m (up 55% from 1Q 2024).
- Net loss: US$24.7m (loss narrowed by 4.7% from 1Q 2024).
- US$0.45 loss per share (improved from US$0.51 loss in 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
PROCEPT BioRobotics Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 5.7%. Earnings per share (EPS) also surpassed analyst estimates by 8.2%.
Looking ahead, revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's shares are down 1.8% from a week ago.
Risk Analysis
Be aware that PROCEPT BioRobotics is showing 2 warning signs in our investment analysis that you should know about...
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGM:PRCT
PROCEPT BioRobotics
A surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally.
Flawless balance sheet and slightly overvalued.
Similar Companies
Market Insights
Advertisement
Weekly Picks
AL
AlexLovell on Rocket Lab ·
Early mover in a fast growing industry. Likely to experience share price volatility as they scale
Fair Value:US$16.25380.9% overvalued
70 followersusers have followed this narrative
1 commentusers have commented on this narrative
18 likesusers have liked this narrative
AG
Agricola on Excellon Resources ·
A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).
Fair Value:CA$31.898.4% undervalued
69 followersusers have followed this narrative
10 commentsusers have commented on this narrative
20 likesusers have liked this narrative
FU
FundamentallySarcastic on Credit Corp Group ·
Moderation and Stabilisation: HOLD: Fair Price based on a 4-year Cycle is $12.08
Fair Value:AU$12.6411.0% overvalued
11 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
Recently Updated Narratives
BA
bactrian on Novo Nordisk ·
A Quality Compounder Marked Down on Overblown Fears
Fair Value:US$9542.0% undervalued
95 followersusers have followed this narrative
8 commentsusers have commented on this narrative
0 likesusers have liked this narrative
YI
yiannisz on Etsy ·
Etsy Stock: Defending Differentiation in a World of Infinite Marketplaces
Fair Value:US$64.459.1% undervalued
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
YI
yiannisz on Align Technology ·
Align Technology Stock: Premium Orthodontics in a Cost-Sensitive World
Fair Value:US$154.623.6% overvalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Popular Narratives
AG
Agricola on Excellon Resources ·
A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).
Fair Value:CA$31.898.4% undervalued
69 followersusers have followed this narrative
10 commentsusers have commented on this narrative
20 likesusers have liked this narrative
AL
AlexLovell on Rocket Lab ·
Early mover in a fast growing industry. Likely to experience share price volatility as they scale
Fair Value:US$16.25380.9% overvalued
70 followersusers have followed this narrative
1 commentusers have commented on this narrative
18 likesusers have liked this narrative
AN
AnalystConsensusTarget on NVIDIA ·
NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
Fair Value:US$253.0225.6% undervalued
1020 followersusers have followed this narrative
6 commentsusers have commented on this narrative
28 likesusers have liked this narrative
Trending Discussion
ST
StevenM on Excellon Resources ·
Interesting analysis, but the price trajectory assumed for the baseline metals is problematic. These assumptions form the foundation for the entire case, and when compared against historical pricing, don’t appear to be grounded in any reasonable precedent. Even accounting for past commodity super-cycles, inflationary periods, or supply constraints, the forecasted pricing for gold, silver, zinc, and lead are well outside what history would suggest is plausible over comparable timeframes. That creates a fragile premise as the conclusions are driven by aggressive inputs rather than underlying market behavior that is realistic. The analysis would be materially stronger if the price assumptions were anchored to historical ranges and prior cycle peaks, with explicit rationale where the model intentionally departs from those patterns. As it stands, the trajectory feels more aspirational than analytical.
1
|1